Virtual Tumors Point to New Drug Combinations for Hard-to-Treat Lung Cancer Mutations
A new quantitative systems pharmacology model spanning all three classes of BRAF-mutant lung cancer predicts that MEK-ERK inhibitor combinations can ...
Tag: NSCLC
Antibody-Drug Conjugate Shows Striking First-Line Results in HER2-Driven Lung Cancer
A multicenter real-world study found that first-line trastuzumab deruxtecan doubled progression-free survival compared with chemotherapy in HER2-altered advanced NSCLC, while ...
Mapping the Hidden Battlefield: Spatial Atlas Tracks How Lung Tumors Evolve to Outsmart Targeted Drugs
A longitudinal spatial multi-omics study reveals how the tumor microenvironment in EGFR-mutant lung cancer remodels in distinct stages as patients ...
A Tiny Dose of Radiation Could Stop Cancer From Spreading to the Liver
A single 2 Gy prophylactic dose of liver radiation reprograms hepatic immune cells via an SAA1–TLR2–CXCL10 signaling axis to recruit ...
c-MET Signaling Reshapes the Lung Cancer Immune Landscape in Space and Metabolism
A new review in the Journal of Translational Medicine argues that c-MET signaling shapes spatially confined, metabolically driven immunosuppressive niches ...
Actinomyces Predicts Immune Therapy Success in Lung Cancer
In a groundbreaking study soon to be published, researchers have unveiled a vital connection between salivary microbial signatures and the ...
M2 Macrophages Shape CD8+ T Cell Response in NSCLC
Recent advancements in cancer immunotherapy have highlighted the crucial role of tumor microenvironment components, particularly M2 macrophages, in shaping the ...
Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
Advances in NSCLC Treatment – Overcoming Osimertinib Resistance and Exploring the Potential of Amivantamab and Lazertinib
In the ever-evolving landscape of cancer treatment, recent breakthroughs in the fight against non-small cell lung cancer (NSCLC) have brought ...
Fighting Osimertinib Resistance in Lung Cancer Treatment
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) ...
POPULAR NEWS
-
Nursing Student Needlestick Reporting Relies on Supervisor Support Rather Than Systems
-
Cross-Sectional Model Identifies Musculoskeletal Injury Risk in Clinical Nurses
-
Biologging Devices Yield Minimal Short-Term Effects on Three European Toad Species
-
Machine Learning Framework Optimizes Seismic Retrofitting for Aging Railway Viaduct Columns